MedTrace Logo

Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-10-30

No results posted yet for this study

Summary

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Conditions

Interventions

DEVICE

Drug Response Predictor® (DRP)

A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Sponsors & Collaborators

  • Amarex Clinical Research

    collaborator OTHER

  • Allarity Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2026-09-30
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03877796 on ClinicalTrials.gov